<SEC-DOCUMENT>0001140361-21-024792.txt : 20210719
<SEC-HEADER>0001140361-21-024792.hdr.sgml : 20210719
<ACCEPTANCE-DATETIME>20210719172957
ACCESSION NUMBER:		0001140361-21-024792
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210713
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210719
DATE AS OF CHANGE:		20210719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		211098760

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10027031_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:btx="http://brooklynitx.com/20210713" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_f415bc8cefcd43b5902e25634b5397ec" contextRef="c20210713to20210713" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_6d760d56c6f247b8860f4abc4e25eb3e" contextRef="c20210713to20210713">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_62dbb6e4b9f64f3e9270315c5c36c49c" contextRef="c20210713to20210713">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_821f306f6b784831a9264952dec668e1" contextRef="c20210713to20210713">140 58TH STREET, BUILDING A</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_40bb32a5cc484f8b99fa85f11da0311b" contextRef="c20210713to20210713">140 58TH STREET, BUILDING A</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_417bad00838b4cc18b468c13188f8fac" contextRef="c20210713to20210713">SUITE 2100</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_536e15c895664d999454310e474dda0a" contextRef="c20210713to20210713">SUITE 2100</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_32af2c526cf34cc997e21080b1f52840" contextRef="c20210713to20210713">BROOKLYN</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_0cb202ce53d34477843f8bae40069abe" contextRef="c20210713to20210713">BROOKLYN</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_be66ba8bca5144ea9d2d0f39b78785f1" contextRef="c20210713to20210713">0000748592</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_568ffa60347948e6bfaad661faa49cf0" contextRef="c20210713to20210713">NYSEAMER</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_dbba1f22b8514396a794fc52bb2e0c20" contextRef="c20210713to20210713">NYSEAMER</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="btx-20210713.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210713to20210713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">
  </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_82233f32fbaf4d62a40ed3f5f0d2b183" contextRef="c20210713to20210713">8-K</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_71a5b55383b54489b5a574a4b2fdb015" contextRef="c20210713to20210713" format="ixt:datemonthdayyearen">July 13, 2021</ix:nonNumeric></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_62dbb6e4b9f64f3e9270315c5c36c49c">BROOKLYN IMMUNOTHERAPEUTICS, INC.</span><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.32%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_7829cc03f4114359b8c1953f59bff988" contextRef="c20210713to20210713" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_63bc1a3b803d4ad8be0997d685dcee94" contextRef="c20210713to20210713">001-11460</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 32.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_06bfc16f0c3a44c6bac69a90f7231e28" contextRef="c20210713to20210713">31-1103425</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33.32%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Commission File Number)</div>
            </td>

    <td style="width: 32.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="-sec-ix-hidden:Fact_40bb32a5cc484f8b99fa85f11da0311b">140 58th Street, Building A, Suite 2100</span>, <span style="-sec-ix-hidden:Fact_536e15c895664d999454310e474dda0a">Suite 2100</span></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="-sec-ix-hidden:Fact_0cb202ce53d34477843f8bae40069abe">Brooklyn</span>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_c076ff465d574dc19e689194a0915859" contextRef="c20210713to20210713" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_5a0071d94ee24c18b2d5bc208563a296" contextRef="c20210713to20210713">11220</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_02f6e47040ff4b6291442666095f8df3" contextRef="c20210713to20210713">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_a72610c6d1d347feb7cf0daa95804e92" contextRef="c20210713to20210713">582-1199</ix:nonNumeric></span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>
<div>
        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>
</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_fc429cb3f1d2444da24121ccda4a9600" contextRef="c20210713to20210713" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2a8988835846499a8d89f7da68111ef0" contextRef="c20210713to20210713" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_58d9f13c9a854a32bea7ca2708c9e667" contextRef="c20210713to20210713" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_3c4278b8ccb44e6483ec0dd7d0eb9745" contextRef="c20210713to20210713" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading symbol</div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 31.84%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_da4f168a1f90408193b3a7bb68ea961c" contextRef="c20210713to20210713">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_084585b3843641e88308e3679a0b90f2" contextRef="c20210713to20210713">BTX</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 31.84%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><span style="-sec-ix-hidden:Fact_dbba1f22b8514396a794fc52bb2e0c20">NYSE American</span><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
        12b-2 of the Securities Exchange Act of 1934:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_789821bfce8345ff9c0e2ee0824a930f" contextRef="c20210713to20210713" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use
        the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;</div>

      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 5.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 13, 2021, we announced that Jay Sial, had been appointed as our Chief Administrative Officer, effective July 15, 2021.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Employment Agreement with Jay Sial</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We entered into an employment agreement, dated July 6, 2021 and effective as of July 15, 2021, with Jay Sial with respect to terms of
        his employment as our Chief Administrative Officer. The compensatory terms of the employment agreement, including equity awards, were approved by the compensation committee of the board of directors, which consists of two disinterested members of
        the board. Mr. Sial&#8217;s hiring, and his employment agreement, were approved by the board.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The employment agreement provides for our at-will employment of Mr. Sial as our Chief Scientific Officer for a term commencing on July
        15, 2021 and continuing until terminated by us or Mr. Sial.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the employment agreement, we will pay Mr. Sial an annual base salary of $350,000, which amount is subject to annual
        review by the board or the compensation committee and subject to adjustment to reflect market practices among our peers in the sole discretion of the board or the compensation committee.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mr. Sial will be eligible to receive an annual cash bonus award in an amount up to 35% of his base salary upon achievement of reasonable
        performance targets set by the board or the compensation committee, each in its sole discretion. The bonus will be determined by the board or the compensation committee and paid annually in March in the year following the performance year on which
        such bonus is based.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In accordance with the terms of the employment agreement, we will grant to Mr. Sial, effective as of July 15, 2021, a time-based
        nonqualified stock option, which we refer to as the Option Grant, and a time-based restricted stock unit grant, which we refer to as the RSU Grant. The Option Grant will cover 71,000 shares of common stock, and the RSU Grant will cover 35,700
        shares of common stock The Option Grant and the RSU Grant each will vest over four years, with vesting generally subject to Mr. Sial&#8217;s continued employment through the relevant vesting date. Consistent with the employment inducement grant rules set
        forth in Section 711(a) of the NYSE American LLC Company Guide, the equity award to Mr. Sial was made as an inducement material to his entering into employment with us and was approved by the compensation committee without need for stockholder
        approval.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If Mr. Sial&#8217;s employment is terminated by us without Cause or by Mr. Sial for Good Reason (each such capitalized term as defined in the
        employment agreement), he will be entitled to, among other things, continued base salary for nine months following the termination date and the total monthly cost of health care continuation coverage pursuant to COBRA for such period.
        Notwithstanding the foregoing, if a termination without Cause or for Good Reason occurs within ninety days before or twelve months after a Change in Control (as defined in the employment agreement), Mr. Sial would become entitled to (a) receive the
        continued-based salary and total monthly cost of health care continuation coverage described in the preceding sentence for a period of twelve months rather than nine months, (b) receive a lump sum payment of his target annual bonus and (c)
        accelerated vesting in full of the Option Grant and the RSU Grant. Any of such severance benefits under the employment agreement are contingent on Mr. Sial entering into and not revoking a general release of claims in favor of our company.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The employment agreement provides for (a) reimbursement of reasonable business expenses, (b) participation in our benefit plans and (c)
        twenty paid vacation days per year.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The employment agreement contains customary covenants related to non-competition and non-solicitation for one year following termination
        of employment, as well as customary covenants related to confidentiality, inventions and intellectual property rights.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The foregoing description of Mr. Sial&#8217;s employment agreement with us does not purport to be complete and is subject
        to, and qualified in its entirety by, the full text of the agreement, which is included as Exhibit 10.1 to this report and is incorporated into this Item 5.02 by reference.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Background of Jay Sial</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mr. Sial previously served as the Chief Financial Officer at Aspen Neurosciences, a biotechnology company, from October 2019 to July
        2021. He was the Chief Financial Officer at University of California Irvine Health from June 2016 to October 2019. Mr. Sial served as Executive Vice President and Chief Financial Officer at Trinity Health/Loyola University Health System from 2012
        to 2016. He holds a Master&#8217;s of Business Administration (Finance) from Virginia Tech and a Bachelor of Arts degree in Economics and Accounting from University of Delhi, India. Mr. Sial is 57 years old.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 8.42%; vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
            </td>

    <td style="width: 1.5%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 90.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Exhibit Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><a href="brhc10027031_ex10-1.htm">10.1+*</a></div>
            </td>

    <td style="width: 1.5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 90.08%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Executive Employment Agreement, dated as of July 6, 2021 and effective as of July 15, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Jay Sial.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><a href="brhc10027031_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1.5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 90.08%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Press release of Brooklyn ImmunoTherapeutics, Inc. dated July 13, 2021.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">+</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Indicates management contract or compensatory plan.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">*</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">An addendum has been omitted pursuant to Item 601(a)(5) of Regulation S-K. We hereby undertake to furnish copies of the omitted addendum upon request by the Securities and Exchange Commission, provided that
                we may request confidential treatment pursuant to Rule 24b&#8209;2 of the Securities Exchange Act of 1934 for the addendum so furnished.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
        behalf by the undersigned, hereunto duly authorized.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.95%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 50.05%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
              <div style="text-align: left; color: rgb(0, 0, 0);">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 50.05%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">&#160;Dated: July 19, 2021</div>
            </td>

    <td style="width: 3.08%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">By:</div>
            </td>

    <td style="width: 46.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">/s/ Howard J. Federoff</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 3.08%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 46.96%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Howard J. Federoff</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 3.08%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 46.96%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div><br /></div>

      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">
  </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10027031_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">




  <font style="font-family: 'Times New Roman'; font-size: 10pt;">
  </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;">Exhibit 10.1<br>
        </font></div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTIVE EMPLOYMENT AGREEMENT</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;) dated as of the first
        date set forth on the signature page hereof, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), and Jay Sial, an individual residing in
        Coto De Caza, California 92679 (&#8220;<font style="font-weight: bold; font-style: italic;">Executive</font>&#8221;) and will be effective as of July 15, 2021 (the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;).&#160; Each of the
        Company and Executive are a &#8220;<font style="font-weight: bold; font-style: italic;">Party</font>,&#8221; and collectively, they are the &#8220;<font style="font-weight: bold; font-style: italic;">Parties</font>.&#8221;</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Company wishes to employ Executive as of the Effective Date; and</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Executive wishes to be employed by the Company as of the Effective Date.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW THEREFORE, in consideration of the above recitals, which are incorporated herein, the mutual covenants and mutual benefits set forth
        herein, and other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the Company and Executive agree as follows:</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Representations and Warranties.</font>&#160; Executive represents and warrants to the Company that Executive is not bound by any restrictive covenants or other obligations or commitments of any kind that would in any way
          prevent, restrict, hinder or interfere with Executive&#8217;s acceptance of employment under the terms and conditions set forth herein or the performance of all duties and services hereunder to the fullest extent of Executive&#8217;s ability and knowledge.&#160;
          Executive understands and acknowledges that Executive is not expected or permitted to use or disclose confidential information belonging to any prior employer in the course of performing Executive&#8217;s duties for the Company.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-weight: bold;">Term of Employment.</font>&#160; As of the Effective Date, the Company will employ Executive and Executive accepts employment by the Company on the terms and conditions herein that shall commence on the Effective Date and
          shall continue until terminated pursuant to Section 5 (the &#8220;<font style="font-weight: bold; font-style: italic;">Employment Period</font>&#8221;).&#160; Notwithstanding anything set forth in Section 5 and for the avoidance of doubt, Executive&#8217;s employment
          is on an at-will basis, meaning that Executive or the Company can terminate Executive&#8217;s employment at any time for any reason or no reason, with or without notice.&#160; The at-will nature of Executive&#8217;s employment cannot be changed except by written
          agreement signed by Executive and the Company.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-weight: bold;">Duties and Functions.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive shall be employed as
          the Chief Administrative Officer (&#8220;<font style="font-weight: bold; font-style: italic;">CAO</font>&#8221;) and shall report to the <a name="z_Hlk56192353"></a>Chief Executive Officer/President (the &#8220;<font style="font-weight: bold; font-style: italic;">Supervisor</font>&#8221;).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees to undertake the
          duties and responsibilities inherent in the positions of CAO, which may encompass different or additional duties as may, from time to time, be assigned by his Supervisor, or the Supervisor&#8217;s designee, and the duties and responsibilities
          undertaken by Executive may be altered or modified from time to time by Supervisor, or by the Supervisor&#8217;s designee.&#160; Executive&#8217;s duties shall include but not be limited to those duties set forth on <u>Addendum A</u>.&#160; Executive agrees to abide
          by the rules, regulations, instructions, personnel practices and policies of the Company and any change thereof which may be adopted at any time by the Company. Notwithstanding the foregoing, during the COVID-19 pandemic, business related travel
          will be subject to the Supervisor&#8217;s and Executive&#8217;s good faith determination that business related travel is necessary.&#160; All applicable COVID-19 travel restrictions, state, local and federal health and safety guidelines, and Company policies
          should be considered in connection with any travel activities.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; During the Employment Period,
          Executive will devote Executive&#8217;s full time and efforts to the business of the Company and will not, without the consent of the Company, engage in consulting work or any trade or business for Executive&#8217;s own account or for or on behalf of any
          other person, firm or corporation that competes, conflicts or interferes with the performance of Executive&#8217;s duties hereunder in any way.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Compensation.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Base Salary</u>:&#160; As
          compensation for Executive&#8217;s services hereunder, the Company agrees to pay Executive a base salary at an annual rate of $350,000, payable in accordance with the Company&#8217;s normal payroll schedule, but in no event less frequently than monthly.&#160;
          Executive&#8217;s base salary shall be reviewed annually by the Board or the Compensation Committee thereof and subject to increase from time to time in the Board&#8217;s and/or the Compensation Committee&#8217;s sole discretion.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Bonus</u>:&#160; Beginning with
          calendar year 2021, Executive shall be eligible to receive an annual cash bonus award in an amount up to a target of 35% of his base salary upon achievement of agreed to reasonable performance targets.&#160; Such performance targets shall be based in
          part upon performance of the Company, and in part on Executive&#8217;s individual performance. The bonus shall be determined by the Board or the Compensation Committee thereof in its sole discretion and paid annually by March 15 of the year following
          the performance year on which such bonus is based.&#160; Except as contemplated by Section 5(c)(i) below, Executive&#8217;s receipt of the bonus, if any, is conditioned on Executive&#8217;s continued employment in good standing as of the date on which such bonus
          is paid, and any such bonus will not be considered earned until such payment date. Executive&#8217;s bonus opportunity shall be reviewed annually by the Board or the Compensation Committee thereof and subject to adjustment to reflect Executive&#8217;s
          performance in the Board&#8217;s and/or the Compensation Committee&#8217;s sole discretion.&#160;Executive&#8217;s bonus for 2021 shall be prorated for the number of days of employment in calendar year 2021 from the Effective Date.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Equity Compensation</u>:</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On the Effective Date, in
          accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, Executive shall be granted two equity awards covering the Company&#8217;s common stock (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Grant</font>&#8221;).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall grant
          Executive a time-based nonqualified stock option grant (the &#8220;<font style="font-weight: bold; font-style: italic;">Option Grant</font>&#8221;) covering 71,000 shares of the Company&#8217;s common stock. The per share exercise price of the Option Grant shall
          equal the closing price of a share of the Company&#8217;s common stock on the grant date. The Option Grant shall vest as to twenty-five percent of the shares covered thereby on the first anniversary of the Effective Date, and 1/36 of the remaining
          shares covered thereby on each monthly anniversary of the Effective Date thereafter, in each case subject to Executive&#8217;s continued employment with the Company through the relevant vesting date.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall grant
          Executive a time-based restricted stock unit grant (the &#8220;<font style="font-weight: bold; font-style: italic;">RSU Grant</font>&#8221;) covering 35,700 shares of the Company&#8217;s common stock. The RSU Grant shall vest in four equal annual installments
          beginning on the first anniversary of the Effective Date, subject to Executive&#8217;s continued employment with the Company through the relevant vesting date, and shall be settled by March 15 of the year following the relevant vesting date.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iv)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All other terms and conditions
          of the Option Grant and the RSU Grant shall be the same as the Company&#8217;s standard forms of grant agreements.&#160; The Option Grant and the RSU Grant are each intended to constitute an &#8220;employment inducement grant&#8221; in accordance with the employment
          inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, and are offered as an inducement material to Executive in connection with the Company&#8217;s hiring of Executive.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(v)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commencing in 2022, Executive
          shall be eligible to receive an equity award under the applicable equity incentive plan of the Company as then in effect, as determined by the Compensation Committee based on Executive&#8217;s performance.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Other Expenses</u>:&#160; In
          addition to the compensation provided for above, the Company agrees to pay or to reimburse Executive during Executive&#8217;s employment for all reasonable, ordinary and necessary, properly documented, business expenses incurred in the performance of
          Executive&#8217;s services hereunder in accordance with Company policy in effect from time to time; provided, however, that the amount available to Executive for such travel, entertainment and other expenses may require advance approval from his
          Supervisor.&#160; Executive shall submit vouchers and receipts for all expenses for which reimbursement is sought.&#160; Notwithstanding any expense reimbursement policy of the Company that may then be in effect, Executive shall be entitled to
          reimbursement without advance approval by his Supervisor of the costs of (i) up to 2 professional conferences up to a total amount of $5,000 annually and (ii) all flights, which, when possible, shall be business class or better for all flights
          for Company travel over four hours in length.&#160; <font style="color: rgb(0, 0, 0);">Executive shall also receive $50/month for costs associated with using his mobile device and home internet for business purposes pursuant to the Company&#8217;s Mobile
            Phone and Home Internet Policy.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Paid Time Off and Paid
            Holidays</u>:&#160; Executive shall accrue up to 20 days of paid time off (&#8220;<font style="font-weight: bold; font-style: italic;">PTO</font>&#8221;) annually for every year of employment, which shall accrue pro rata in the Company&#8217;s regular payroll (up to
          a maximum of 42 days).&#160; PTO shall accrue pro rata in the Company&#8217;s regular payroll on a calendar basis and shall be subject to the Company&#8217;s PTO policies in place from time to time and all applicable state and local law.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any accrued, unused PTO can be carried over to the following calendar year up to a maximum of 60 days (the &#8220;Cap&#8221;).&#160;&#160; Once the Cap is
        reached, no further PTO will accrue until some accrued time is used.&#160; When some PTO is used, PTO will begin to accrue again.&#160; <font style="color: rgb(0, 0, 0);">Accrued, unused PTO shall be paid upon separation of employment consistent with
          applicable law.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In addition to the enumerated paid Company holidays, Executive shall also be entitled to up to seven (7) paid floating holidays per
        calendar year.&#160; Unused paid floating holidays shall expire on December 31 each year and shall not be paid upon separation.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Executive may also be entitled to additional paid or unpaid leave under Company policy and applicable law.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fringe Benefits</u>.&#160; In
          addition to Executive&#8217;s compensation provided by the foregoing, Executive shall be entitled to all benefits available generally to Company employees pursuant to Company programs which may now or, if not terminated, shall hereafter be in effect,
          or that may be established by the Company, as and to the extent any such programs are or may from time to time be in effect, as determined by the Company <a name="mark"></a><a name="CurrSpot"></a>and the terms hereof, subject to the applicable
          terms and conditions of the benefit plans in effect at that time.&#160; Nothing herein shall affect the Company&#8217;s ability to modify, alter, terminate or otherwise change any benefit plan it has in effect at any given time, to the extent permitted by
          law.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Reimbursements</u>.&#160; With
          respect to any reimbursement of expenses of Executive, such reimbursement of expenses shall be subject to the following conditions: (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for
          reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (iii) the right to reimbursement shall not be subject to
          liquidation or exchange for another benefit.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Termination.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Executive</u>.
          Executive may terminate the employment relationship at any time by giving the Company written notice, with such termination taking effect upon written notice of the termination being provided to the Company. If Executive chooses to terminate the
          employment relationship other than for Good Reason (defined below), Executive will not be entitled to and shall not receive any compensation or benefits of any type following the effective date of termination, other than (i) payment of base
          salary through the last day of employment, (ii) payment for any accrued but unused PTO consistent with this agreement and the Company&#8217;s policies then in effect, (iii) reimbursement for unreimbursed business expenses properly incurred by
          Executive, which shall be subject to and paid in accordance with the Company&#8217;s expense reimbursement policy, and (iv) any right to continued benefits required by law or under the Company&#8217;s employee benefit plans and vested as of the termination
          date (the &#8220;Accrued Obligations&#8221;). If Executive terminates the employment relationship for Good Reason (defined below), Executive will be entitled to the Accrued Obligations and the Non-CIC Termination Compensation or CIC Termination Compensation,
          as applicable and described below, subject to the terms, conditions and restrictions set forth in Section 5(c)(ii).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold; font-style: italic;">Good Reason</font>&#8221; means the occurrence of any of the following without Executive&#8217;s express written consent: (A) a material reduction in Executive&#8217;s base salary or maximum annual bonus, in each case set forth in
          Section 4; (B) a relocation of Executive to a facility or location that is more than fifty (50) miles from Executive&#8217;s primary place of employment as of the Effective Date and represents a material increase in Executive&#8217;s commuting distance; (C)
          a material diminution in Executive&#8217;s authority, position, duties, or responsibilities individually or taken as a whole and including any such diminution that takes place following a Change in Control; or (D) a material breach by the Company of
          the terms of this Agreement or any other agreement between the Company and Executive; provided, that no such event described above will constitute Good Reason unless: (x) Executive gives notice to the Company specifying the condition or event
          relied upon for such termination within sixty (60) days of the initial existence of such event; and (y) the Company fails to cure the condition or event constituting Good Reason within thirty (30) days following receipt of such notice (the &#8220;<font style="font-weight: bold; font-style: italic;">Cure Period</font>&#8221;).&#160; If the Company fails to remedy the condition constituting Good Reason during the applicable Cure Period, Executive&#8217;s termination of employment must occur, if at all, within
          ninety (90) days following the last day of such Cure Period in order for such termination as a result of such condition to constitute a termination for Good Reason.&#160; For purposes of this Agreement, &#8220;Change in Control&#8221; means as defined in the
          Company&#8217;s 2020 Stock Incentive Plan.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Company for
            Cause</u>.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At any time during the
          Employment Period, the Company may terminate Executive&#8217;s employment for Cause (defined below), with such termination taking effect upon the later of written notice of the termination for Cause being provided to Executive or the expiration of any
          applicable cure period related thereto (provided that Executive may be relieved from his duties hereunder during such cure period in the reasonable direction of the Board).&#160; If Executive&#8217;s employment is terminated for Cause, Executive will not be
          entitled to and shall not receive any compensation or benefits of any type following the effective date of termination, other than the Accrued Obligations, and shall forfeit the Option Grant and the RSU Grant, in each case whether vested or
          unvested.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Cause</font>&#8221; shall be defined as:<font style="color: rgb(0, 0, 0);"> (A) in connection with Executive&#8217;s services hereunder, Executive commits a material act of fraud or material act of dishonesty with respect to the
            Company, which act causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company; (B) Executive is convicted of (or pleads guilty or nolo contendere to) a felony or a crime involving moral
            turpitude, which demonstrably causes material economic or material reputational harm to the Company; (C) Executive engages in negligence or willful misconduct in the performance of his duties hereunder that materially violates the Company&#8217;s
            policies and which misconduct causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company; (D) Executive willfully refuses to follow the lawful written directions of his Supervisor, the
            Supervisor&#8217;s designee, or the Board; (E) Executive materially breaches any material provision of any proprietary information and inventions agreement with the Company; or (F) Executive breaches any Restrictive Covenant as defined in Section
            5(c)(ii).&#160; Notwithstanding anything in this Agreement or elsewhere to the contrary, if an event or occurrence that is alleged to constitute Cause is curable (as determined by the Board in good faith), the Company may terminate Executive&#8217;s
            employment for Cause only if (x) the Company gives Executive notice of termination prior to the termination and within thirty (30) days after the Board learns of the event or occurrence that is alleged to constitute Cause, specifying the
            grounds upon which Cause is alleged, (y) Executive fails to cure such grounds for Cause within thirty (30) days after Executive receives such notice, and (z) the termination occurs within sixty (60) days after such event or occurrence.&#160; For
            purposes of this Agreement, no act or failure to act, on Executive&#8217;s part, will be considered &#8220;willful&#8221; unless it is done, or omitted to be done, by Executive in bad faith or without reasonable belief that Executive&#8217;s action or omission was in
            the best interests of the Company.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Company
            Without Cause</u>.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company may terminate
          Executive without Cause immediately by giving Executive written notice of such termination.&#160; Subject to the conditions set forth in Section 5(c)(ii), if Executive&#8217;s employment is terminated by the Company without Cause, in addition to the Accrued
          Obligations, Executive shall be entitled to (i) continued base salary for nine (9) months following date of such termination (the &#8220;<font style="font-weight: bold; font-style: italic;">Severance Period</font>&#8221;) paid pursuant to the Company's
          normal payroll practices; and (ii) if Executive and/or Executive&#8217;s covered dependents timely elect(s) to receive health care continuation coverage pursuant to COBRA, the total monthly cost of coverage for Executive (and such covered dependents)
          during the Severance Period, provided, for the avoidance of doubt, that such covered dependents participated in the Company&#8217;s health plans prior to such termination, and provided, further, that if at any time the Company determines that its
          payment of Executive&#8217;s (or Executive&#8217;s eligible dependents&#8217;) premiums would result in a violation of law, then in lieu of providing the premiums described above, the Company will instead pay Executive a fully taxable monthly cash payment in an
          amount equal to the applicable premiums for such month, with such monthly payment being made on the last day of each month for the remainder of the Severance Period (together, the &#8220;<font style="font-weight: bold; font-style: italic;">Non-CIC
            Termination Compensation</font>&#8221;). Notwithstanding the foregoing, if Executive&#8217;s employment is terminated by the Company without Cause or by Executive for Good Reason, in each case during the ninety (90) days prior to or twelve (12) month
          period following a Change in Control, (i) the Executive shall receive the Non-CIC Termination Compensation as described above except that the Severance Period shall equal twelve (12) months in lieu of nine (9) months, (ii) Executive shall receive
          a lump-sum payment of Executive&#8217;s target annual bonus and (iii) Executive shall become fully vested in the Option Grant and the RSU Grant (together, the &#8220;<font style="font-weight: bold; font-style: italic;">CIC Termination Compensation</font>&#8221;).
          The Non-CIC Termination Compensation and the CIC Termination Compensation shall, as applicable and in each case, be subject to the terms, conditions and restrictions set forth below in Section 5(c)(ii).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive shall not be
          entitled to any Non-CIC Termination Compensation or CIC Termination Compensation unless (A) Executive complies with all surviving provisions of any non-competition agreement, non-solicitation agreement, or confidentiality agreement or invention
          assignment agreement signed by Executive, including those contained in this Agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Restrictive Covenants</font>&#8221;) and (B) Executive executes and delivers to the Company, and does not
          revoke a separation agreement and general release in form and substance reasonably acceptable to the Company within thirty (30) days after Executive&#8217;s separation date, by which Executive releases the Company from any obligations and liabilities
          of any type whatsoever, except for the Company&#8217;s obligations with respect to, as applicable, the Non-CIC Termination Compensation or the CIC Termination Compensation (the &#8220;<font style="font-weight: bold; font-style: italic;">Release</font>&#8221;).&#160;
          Such Release shall not affect Executive&#8217;s right to indemnification, if any, for actions taken within the scope of Executive&#8217;s employment. The Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, shall begin, or if
          lump-sum, be paid on the first payroll following the Release becoming irrevocable; provided, however, if the thirty (30) day period during which Executive has discretion to execute or revoke the Release straddles two taxable years of Executive,
          then the Company shall pay the Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, starting in the second of such taxable years, regardless of which taxable year Executive actually delivers the executed Release to
          the Company.&#160; The Parties hereto acknowledge that the Non-CIC Termination Compensation and the CIC Termination Compensation, as applicable, to be provided under Section 5(c)(i) is to be provided in consideration for the above-specified Release.&#160;
          If Executive breaches any of the Restrictive Covenants at any time during the Severance Period, (1) the Company will have no further obligation to pay Executive any unpaid Non-CIC Termination Compensation or CIC Termination Compensation, as
          applicable, (2) Executive must repay any portion of the Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, already paid to him, and (3) the Company may take any additional action to enforce its rights under the
          Restrictive Covenants.&#160; Finally, if Executive becomes employed during the Severance Period, Executive will no longer be entitled to receive his continued base salary from the Company.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Disqualification for Other
            Severance</u>.&#160; The Non-CIC Termination Compensation and the CIC Termination Compensation described in this Section 5(c) is intended to supersede any other similar compensation provided by any Company policy, plan or practice.&#160; Therefore,
          Executive shall be disqualified from receiving any similar compensation under any other Company severance policy, plan or practice, if any. Notwithstanding the foregoing, Executive shall continue to be eligible for any benefits pursuant to the
          terms of any health or retirement plan sponsored by the Company, subject to and in accordance with the terms of the applicable plan.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination for Executive&#8217;s
            Permanent Disability</u>.&#160; To the extent permissible under applicable law, in the event Executive becomes permanently disabled during employment with the Company, the Company may terminate this Agreement by giving thirty (30) days' notice to
          Executive of its intent to terminate, and unless Executive resumes performance of the duties set forth in Section 3 within five (5) days of the date of the notice and continues performance for the remainder of the notice period, this Agreement
          shall terminate at the end of the thirty (30) day period.&#160; For purposes of this Agreement, &#8220;permanently disabled&#8221; shall mean if Executive is considered totally disabled under any group disability plan maintained by the Company and in effect at
          that time, or in the absence of any such plan, under applicable Social Security regulations, to the extent not inconsistent with applicable law.&#160; In the event of any dispute under this Section 5(d), Executive shall submit to a physical
          examination by a licensed physician mutually satisfactory to the Company and Executive, the cost of such examination to be paid by the Company, and the determination of such physician shall be determinative.&#160; In the event the Executive is
          terminated pursuant to this Section 5(d), Executive will be entitled to the Accrued Obligations and the Non-CIC Termination Compensation, subject to the terms, conditions and restrictions set forth in Section 5(c)(ii).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination Due to
            Executive&#8217;s Death</u>.&#160; This Agreement will terminate immediately upon Executive&#8217;s death and the Company shall not have any further liability or obligation to Executive, Executive&#8217;s executors, heirs, assigns or any other person claiming under
          or through Executive&#8217;s estate, except that Executive&#8217;s estate shall receive any Accrued Obligations. In addition, Executive&#8217;s estate shall be entitled to accelerated vesting of the portion of the Option Grant and the RSU Grant that would have
          otherwise vested during the nine (9) month period following such termination.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Continuing Obligations</u>.&#160;
          The obligations imposed on Executive with respect to non-competition, non-solicitation, confidentiality, non-disclosure and assignment of rights to inventions or developments in this Agreement or any other agreement executed by the Parties shall
          continue, notwithstanding the termination of the employment relationship between the Parties and regardless of the reason for such termination.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Company Property.&#160; </font>All correspondence, records, documents, software, promotional materials, and other Company property, including all copies, which come into Executive&#8217;s possession by, through or in the course
          of Executive&#8217;s employment, regardless of the source and whether created by Executive, are the sole and exclusive property of the Company, and immediately upon the termination of Executive&#8217;s employment, or at any time the Company shall request,
          Executive shall return to the Company all such property of the Company, without retaining any copies, summaries or excerpts of any kind or in any format whatsoever.&#160; Executive shall not destroy any Company property, such as by deleting electronic
          mail or other files, other than in the normal course of Executive&#8217;s employment.&#160; Executive further agrees that should Executive discover any Company property or Confidential Information in Executive&#8217;s possession after the return of such property
          has been requested, Executive agrees to return it promptly to Company without retaining copies, summaries or excerpts of any kind or in any format whatsoever.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">7.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Non-Competition and Non-Solicitation.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive agrees and
          acknowledges that, in connection with Executive&#8217;s employment with the Company, Executive will be provided with access to and become familiar with confidential and proprietary information and trade secrets belonging to the Company and its
          affiliates.&#160; Accordingly, in consideration of Executive&#8217;s employment with the Company pursuant to this Agreement, and other good and valuable consideration, the receipt of which is hereby acknowledged, Executive agrees that, while Executive is in
          the employ of the Company and/or any of its affiliates, Executive shall not, either on Executive&#8217;s own behalf or on behalf of any third party, except on behalf of the Company or one of its affiliates, directly or indirectly:</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; engage
          directly or indirectly in the Business (as defined below) anywhere in the Restricted Territory (as defined below) or directly or indirectly be or become an officer, director, stockholder, owner, affiliate, partner, member, investor, joint
          venture, employee, agent, representative, consultant, lender, advisor, manager of, for or to, or otherwise be or become associated with or acquire or hold (of record, beneficially or otherwise) any direct or indirect interest in, any business or
          enterprise engaged directly or indirectly in the Business (as defined below) anywhere in the Restricted Territory (as defined below).&#160; As used herein, (A) the term &#8220;<font style="font-weight: bold; font-style: italic;">Business</font>&#8221; shall mean
          the business of development and manufacturing of a cytokine immunotherapy (related to or derived from human source material) for cancer treatment and RNA based gene therapy and editing of MSC, HSC, TILs and T-Cells, and (B) the term &#8220;<font style="font-weight: bold; font-style: italic;">Restricted Territory</font>&#8221; shall mean worldwide.&#160; The foregoing restriction shall not be construed to prohibit the ownership by Executive as a passive investment of shares of capital stock of a
          publicly-held corporation that engages in the Business if (x) such shares are actively traded on an established national securities market in the United States or any other foreign securities exchange, (y) the number of shares of such
          corporation&#8217;s capital stock that are owned beneficially (directly or indirectly) by Executive and the number of shares of such corporation&#8217;s capital stock that are owned beneficially (directly or indirectly) by Executive&#8217;s affiliates collectively
          represent less than one percent (1%) of the total number of shares of such corporation&#8217;s capital stock outstanding, and (z) neither Executive nor any affiliate of Executive is otherwise associated directly or indirectly with such corporation or
          with any affiliate of such corporation; or</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;attempt in
          any manner to solicit, induce or attempt to induce any business, enterprise, or individual who has a business relationship with the Company (including any customer, licensee, supplier, manufacturer or vendor) (x) to cease doing business with the
          <a name="z_Hlk56193364"></a>Company or any of its affiliates, (y) to diminish or materially alter in a manner harmful to the Company or any of its affiliates, or any of their affiliates such business, enterprise, or individual&#8217;s relationship with
          the Company or any of its affiliates, or (z) to purchase, contract for or receive any products or services from any business or enterprise (other than the Company or any of its affiliates) that engages in the Business anywhere within the
          Restricted Territory.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees and
          acknowledges that for one (1) year period following the end of Executive&#8217;s employment for any reason,&#160; Executive shall not, either on Executive&#8217;s own behalf or on behalf of any third party (A) directly or indirectly hire any employee, independent
          contractor, or consultant or any person who was an employee, independent contractor, or consultant of the Company within the preceding six (6) months, or (B) directly or indirectly encourage, induce, attempt to induce, solicit or attempt to
          solicit (on Executive&#8217;s own behalf or on behalf of any other business, enterprise, or individual) any employee, independent contractor, or consultant to leave or curtail his or her employment or engagement with the Company or any of its
          affiliates; provided, however, that notwithstanding the foregoing, this Section 7(a)(iii) shall not prevent Executive from undertaking general solicitations of employment not targeted at employees, independent contractors, or consultants of the
          Company or any of its affiliates (so long as Executive does not, directly or indirectly, hire any such employee, independent contractor, or consultant).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties agree that the
          relevant public policy aspects of post-employment restrictive covenants have been discussed, and that every effort has been made to limit the restrictions placed upon Executive to those that are reasonable and necessary to protect the Company&#8217;s
          legitimate interests.&#160; Executive acknowledges that, based upon Executive&#8217;s education, experience, and training, the restrictions set forth in this Section 7 will not prevent Executive from earning a livelihood and supporting himself and
          Executive&#8217;s family during the relevant time period.&#160; Executive further acknowledges that, because the Company markets its products and services throughout the Restricted Territory, a more narrow geographic limitation on the restrictive covenants
          set forth above would not adequately protect the Company&#8217;s legitimate business interests.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any restriction set forth in
          this Section 7 is found by any court of competent jurisdiction or arbitrator to be unenforceable because it extends for too long a period of time or over too great a range of activities or geographic area, it shall be interpreted to extend over
          the maximum period of time, range of activities or geographic area as to which it may be enforceable.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The restrictions contained in
          Section 7 are necessary for the protection of the business and goodwill of the Company and/or its affiliates and are considered by Executive to be reasonable for such purposes.&#160; <a name="z_Hlk55783292"></a>Executive agrees that any material
          breach of Section 7 will result in irreparable harm and damage to the Company and/or its affiliates that cannot be adequately compensated by a monetary award.&#160; Accordingly, it is expressly agreed that in addition to all other remedies available
          at law or in equity (including, without limitation, money damages from Executive), the Company and/or such affiliate shall be entitled to a temporary restraining order, preliminary injunction or such other form of injunctive or equitable relief
          as may be issued by any court of competent jurisdiction or arbitrator to restrain or enjoin Executive from breaching any such covenant or provision or to specifically enforce the provisions hereof, without the need to post any bond or other
          security.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; The existence of a claim,
          charge, or cause of action by Executive against the Company shall not constitute a defense to the enforcement by the Company of the foregoing restrictive covenants.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The provisions of this Section
          7 shall apply regardless of the reason for the termination of Executive&#8217;s employment.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Non-Circumvention / Non-Interference.&#160; </font>Executive acknowledges and agrees that during the Employment Period, other than acting on behalf of the Company in his capacity as an employee of the Company, Executive
          shall not, and shall not authorize or permit any of his Representatives to, directly or indirectly, interfere, discuss, contact, initiate, or engage, encourage, solicit, initiate, facilitate or continue inquiries to any third parties concerning
          any business opportunities related to the Company.&#160; It is understood that, during the Employment Period, without previous written consent from the Company, the Executive&#160; will not enter, either directly or indirectly, into any discussions,
          solicit or accept offers, enter into any agreements, conduct negotiations with or otherwise engage in any other independent communications unrelated to the Company&#8217;s business with: any third party to whom Executive was introduced to by any
          member, shareholder, officer, director, employee, agent, customer, supplier, vendor, or other representative of the Company, Factor Bioscience, or Novellus, Inc.; any third party to whom Executive was informed of by any member, shareholder,
          officer, director, employee, agent, customer, supplier, vendor, or other representative of Company, Factor Bioscience, or Novellus, Inc. or any employee, financial partner, investor, contractor of the Company. For purposes of this Agreement,
          "Representatives" means, as to Company, its affiliates, and respective consultants (including attorneys, financial advisors and accountants).&#160; Further, after termination of Executive&#8217;s employment with the Company, he will not take any action or
          omit to take an action intended to interfere with existing contractual and or business relationships with the Company in a manner prohibited by law.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold;">Protection of Confidential Information.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive agrees that all
          information, whether or not in writing, relating to the business, technical or financial affairs of the Company and that is generally understood in the industry as being confidential and/or proprietary information, is the exclusive property of
          the Company.&#160; Executive agrees to hold in a fiduciary capacity for the sole benefit of the Company all secret, confidential and/or proprietary information, knowledge, and data, including trade secrets, relating to the Company or any of its
          affiliates obtained during Executive&#8217;s employment with the Company or any of its predecessors or affiliates, including but not limited to any trade secrets, confidential or secret designs, website technologies, content, processes, formulae,
          plans, manuals, devices, machines, know-how (including without limitation the manufacturing of IRX-2), methods, compositions, ideas, improvements, financial and marketing information, costs, pricing, sales, sales volume, salaries, methods and
          proposals, customer and prospective customer lists, customer identities, customer volume, or customer contact information, identity of key personnel in the employ of customers and prospective customers, amount or kind of customer&#8217;s purchases from
          the Companies or their affiliates, manufacturer lists, manufacturer identities, manufacturer volume, or manufacturer contact information, identity of key personnel in the employ of manufacturers, amount or kind of the Companies&#8217; or their
          affiliates&#8217; purchases from manufacturers, system documentation, hardware, engineering and configuration information, computer programs, source and object codes (whether or not patented, patentable, copyrighted or copyrightable), related software
          development information, inventions or other confidential or proprietary information (including without limitation information relating to IRX-2 and its intellectual property that has not yet issued) belonging to the Companies or their affiliates
          or directly or indirectly relating to the Companies&#8217; or their affiliates&#8217; business and affairs (&#8220;<font style="font-weight: bold; font-style: italic;">Confidential Information</font>&#8221;).&#160; Executive agrees that Executive will not at any time, either
          during the Employment Period or the Confidentiality Period (as defined below), disclose to anyone any Confidential Information, or utilize such Confidential Information for Executive&#8217;s own benefit, or for the benefit of third parties without
          written approval by an officer of the Company.&#160; For purposes of this section, the &#8220;<font style="font-weight: bold; font-style: italic;">Confidentiality Period</font>&#8221; means so long as such information, data, or material remains confidential.&#160;
          Executive further agrees that all memoranda, notes, records, data, schematics, sketches, computer programs, prototypes, or written, photographic, magnetic or other documents or tangible objects compiled by Executive or made available to Executive
          during the Employment Period concerning the business of the Company and/or its clients, including any copies of such materials, shall be the property of the Company and shall be delivered to the Company on the termination of Executive&#8217;s
          employment, or at any other time upon request of the Company.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event Executive is
          questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to any Confidential Information or any other secret or confidential work of the Company, or
          concerning any fact or circumstance relating thereto, or in the event that Executive becomes aware of the unauthorized use of Confidential Information by any party, whether competitive with the Company or not, Executive will promptly notify an
          executive officer of the Company.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Court-Ordered Disclosure</u>.&#160;
          In the event that, at any time during Executive&#8217;s employment with the Company or at any time thereafter, Executive receives a request to disclose&#160; any Confidential Information under the terms of a subpoena or order issued by a court or by a
          governmental body, Executive agrees to notify the Company immediately of the existence, terms, and circumstances surrounding such request, to consult with the Company on the advisability of taking legally available steps to resist or narrow such
          request; and, if disclosure of such Confidential Information is required to prevent Executive from being held in contempt or subject to other penalty, to furnish only such portion of the Confidential Information as, in the written opinion of
          counsel satisfactory to the Company, Executive is legally compelled to disclose, and to exercise Executive&#8217;s best efforts to obtain an order or other reliable assurance that confidential treatment will be accorded to the disclosed Confidential
          Information.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Defend Trade Secrets Act</u>.&#160;
          Pursuant to the Defend Trade Secrets Act of 2016, Executive acknowledges that Executive shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence
          to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed
          in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Executive files a demand for arbitration alleging retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret
          to Executive&#8217;s attorney and may use the trade secret information in the arbitration proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to an order of
          the arbitrator.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">10.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Intellectual Property.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Disclosure of Inventions</u>.&#160;
          Executive will promptly disclose in confidence to the Company all inventions, improvements, processes, products, designs, original works of authorship, formulas, processes, compositions of matter, computer software programs, Internet products and
          services, e-commerce products and services, e-entertainment products and services, databases, mask works, trade secrets, product improvements, product ideas, new products, discoveries, methods, software, uniform resource locators or proposed
          uniform resource locators (&#8220;<font style="font-weight: bold; font-style: italic;">URLs</font>&#8221;), domain names or proposed domain names, any trade names, trademarks or slogans, which may or may not be subject to or able to be patented, copyrighted,
          registered, or otherwise protected by law (the &#8220;<font style="font-weight: bold; font-style: italic;">Inventions</font>&#8221;) that Executive makes, conceives or first reduces to practice or creates, either alone or jointly with others, during the
          Employment Period, whether or not in the course of Executive&#8217;s employment (i) that result from any work performed by the Executive for the Company; (ii) that are developed from using the Company's equipment, supplies, facilities or trade secret
          information; or (iii) that relate at the time of conception or reduction to practice of the invention to the Company's business, or actual or demonstrably anticipated research or development of the Company.&#160; The requirements of this Section 10(a)
          shall not apply to any Inventions that qualify fully under the provisions of California Labor Code section 2870 (the terms of which are set forth on <u>Addendum B</u> to this Agreement), specifically, any Invention that Executive developed
          entirely on Executive&#8217;s own time without using the Employer&#8217;s equipment, supplies, facilities, or trade secret information except for those Inventions that either (i) relate at the time of conception or reduction to practice of the Invention to
          the Employer&#8217;s business, or Employer&#8217;s actual or demonstrably anticipated research or development; or (ii) result from any work performed by Executive for Employer.&#160; Executive shall bear the full burden of proving to the Employer that an
          Invention qualifies fully under California Labor Code section 2870.&#160; The foregoing requirements of Section 10(a) apply, and whether or not such Inventions are patentable, copyrightable or able to be protected as trade secrets, or otherwise able
          to be registered or protected by law. Executive has provided a list of prior Inventions as <u>Addendum C</u>, which will not be subject to the provisions of this Section 10.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Assignment of Company
            Inventions; Work for Hire</u>.&#160; Executive agrees that all Inventions that (i) are developed using equipment, supplies, facilities or trade secrets of the Company, (ii) result from work performed by Executive for the Company, or (iii) relate to
          the Company&#8217;s business or current or anticipated research and development (the &#8220;<font style="font-weight: bold; font-style: italic;">Company Inventions</font>&#8221;), will be the sole and exclusive property of the Company and the Executive hereby
          agrees to irrevocably assign to the Company any such Company Inventions.&#160; Executive further acknowledges and agrees that any copyrightable works prepared by Executive within the scope of Executive&#8217;s employment are &#8220;works for hire&#8221; under the
          Copyright Act and that the Company will be considered the author and owner of such copyrightable works from the moment of their creation and fixation in tangible media.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Assignment of Other Rights</u>.&#160;
          In addition to the foregoing assignment of Company Inventions to the Company, Executive hereby irrevocably transfers and assigns to the Company:&#160; (i) all worldwide patents, patent applications, copyrights, mask works, trade secrets and other
          intellectual property rights in any Company Invention; and (ii) any and all &#8220;Moral Rights&#8221; (as defined below) that Executive may have in or with respect to any Company Invention.&#160; Executive also hereby forever waives and agrees never to assert
          any and all Moral Rights Executive may have in or with respect to any Company Invention, even after termination of Executive&#8217;s work on behalf of the Company.&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Moral Rights</font>&#8221; means any
          rights to claim authorship of an Company Invention, to object to or prevent the modification of any Company Invention, or to withdraw from circulation or control the publication or distribution of any Company Invention, and any similar right,
          existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Assistance</u>.&#160; Executive
          agrees to assist the Company in every proper way to obtain for the Company and enforce patents, copyrights, mask work rights, trade secret rights and other legal protections for the Company Inventions in any and all countries.&#160; Executive will
          execute any documents that the Company may reasonably request for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections.&#160; Executive&#8217;s obligations under this section will continue
          beyond the termination of Executive&#8217;s employment with the Company, provided that the Company will compensate Executive at a reasonable rate after such termination for time or expenses actually spent by Executive at the Company&#8217;s request on such
          assistance.&#160; Executive appoints the Secretary of the Company as Executive&#8217;s attorney-in-fact to execute documents on Executive&#8217;s behalf for this purpose.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Publicity; Non-disparagement.&#160; </font>Neither Party shall issue, without consent of the other Party, any press release or make any public announcement with respect to this Agreement or the employment relationship
          between them, or the ending of such relationship.&#160; Following the date of this Agreement and regardless of any dispute that may arise in the future, Executive agrees that Executive will not disparage, criticize or make statements which are
          negative, detrimental or injurious to Company or any of its affiliates, or any of their affiliates to any individual, company or client, including within the Company.<a name="z_Ref1826681"></a>&#160; This <u>Section 11</u> does not, in any way,
          restrict or impede the parties hereto from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or
          an authorized government agency, provided that such compliance does not exceed that required by the law, regulation, or order.&#160; Nothing contained herein shall prevent Executive from providing true testimony to the extent required within any legal
          proceeding (or in any discovery in connection therewith) or investigation by a governmental authority.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">12.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Binding Agreement.</font>&#160; This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their heirs, personal representatives, successors and assigns.&#160; Executive acknowledges and agrees that
          the Company may, in its sole discretion, assign this Agreement (i) to an affiliate of the Company at any time, or (ii) in the event the Company is acquired, is a non-surviving party in a merger, or transfers substantially all of its assets, to
          the transferee or surviving company, in each case without being required to obtain Executive&#8217;s consent.&#160; The Parties understand that the obligations of Executive are personal and may not be assigned by him.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">13.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Entire Agreement.</font>&#160; This Agreement contains the entire understanding of Executive and the Company with respect to employment of Executive.&#160; This Agreement may not be amended, waived, discharged or terminated
          orally, but only by an instrument in writing, specifically identified as an amendment to this Agreement, and signed by all Parties.&#160; By entering into this Agreement, Executive certifies and acknowledges that Executive has carefully read all of
          the provisions of this Agreement and that Executive voluntarily and knowingly enters into said Agreement.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">14.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Severability.</font>&#160; Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be deemed severable from the remainder of this Agreement, and the
          remaining provisions contained in this Agreement shall be construed to preserve to the maximum permissible extent the intent and purposes of this Agreement.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">15.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Tax Consequences</font>.&#160; If any payment or benefit the Executive would receive pursuant to this Agreement (<font style="font-weight: bold; font-style: italic;">&#8220;Payment&#8221;</font>) would (a) constitute a &#8220;<font style="font-weight: bold; font-style: italic;">Parachute Payment</font>&#8221; within the meaning of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;<font style="font-weight: bold; font-style: italic;">Excise Tax</font>&#8221;), then such Payment shall be equal to the Reduced Amount.&#160; The &#8220;<font style="font-weight: bold; font-style: italic;">Reduced Amount</font>&#8221; shall be either (i) the largest
          portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (ii) the largest portion, up to and including the total of the Payment, whichever amount, after taking into account all applicable federal,
          state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#8217;s receipt, on an after-tax basis, of the greatest economic benefit notwithstanding that all or
          some portion of the Payment may be subject to the Excise Tax.&#160; If a reduction in payments or benefits constituting Parachute Payments<font style="font-weight: bold;">&#160;</font>is necessary so that the Payment equals the Reduced Amount, reduction
          shall occur in the manner that results in the greatest economic benefit for Executive to the extent permitted by Section 409A of the Code, to the extent applicable, and Section 280G of the Code.&#160; Except as otherwise specifically provided in this
          Agreement, the Company will have no obligation to any person entitled to the benefits of this Agreement with respect to any tax obligation any such person incurs as a result of or attributable to this Agreement, including all supplemental
          agreements and employee benefits plans incorporated by reference therein, or arising from any payments made or to be made under this Agreement or thereunder.&#160; All determinations under this <font style="font-weight: bold;">Section 15</font> will
          be made by an actuarial firm, accounting firm, law firm, or consulting firm experienced and generally recognized in 280G matters (the &#8220;<font style="font-weight: bold;">280G Firm</font>&#8221;) that is chosen by the Company prior to a change in
          ownership or control of a corporation (within the meaning of Treasury regulations under Section 280G of the Code). The 280G Firm shall be required to evaluate the extent to which payments are exempt from Section 280G as reasonable compensation
          for services rendered before or after the Change in Control. All fees and expenses of the 280G Firm shall be paid solely by the Company or its successor. The Company and Executive shall furnish the tax firm such information and documents as the
          tax firm may reasonably request in order to make its required determination.&#160; The 280G Firm will provide its calculations, together with detailed supporting documentation, to the Company and Executive as soon as practicable following its
          engagement.&#160; Any good faith determinations of the 280G Firm made hereunder will be final, binding and conclusive upon the Company and Executive.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">16.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Withholding.&#160; </font>The Company shall have the right to withhold from any amount payable hereunder any federal, state, local and foreign taxes in order for the Company to satisfy any withholding tax obligation it
          may have under any applicable law or regulation. Notwithstanding any other provision of this Agreement, the Company does not guarantee any particular tax result for Executive with respect to any payment provided to Executive hereunder, and
          Executive shall be solely responsible for any taxes imposed on Executive with respect to any such payment.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">17.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-weight: bold;">Section 409A.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement is intended to
          comply with, or otherwise be exempt from, Section 409A of the Code and any regulations and Treasury guidance promulgated thereunder (&#8220;<font style="font-weight: bold; font-style: italic;">Section 409A of the Code</font>&#8221;) and shall be construed
          and administered in accordance with such intent.&#160; Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A of the Code or an
          applicable exemption. Any payments under this Agreement that may be excluded from Section 409A of the Code either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A of
          the Code to the maximum extent possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be
          liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Executive on account of non-compliance with Section 409A of the Code.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of Section 409A of
          the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.&#160; In no event may Executive, directly or indirectly, designate the calendar year of payment.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to any
          reimbursement of expenses of, or any provision of in-kind benefits to, Executive, as specified under this Agreement, such reimbursement of expenses or provision of in-kind benefits shall be subject to the following conditions: (1) the expenses
          eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical
          reimbursement arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the Code; (2) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was
          incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;Termination of employment,&#8221;
          &#8220;resignation,&#8221; or words of similar import, as used in this Agreement means, for purposes of any payments under this Agreement that are payments of deferred compensation subject to Section 409A of the Code, Executive&#8217;s &#8220;separation from service&#8221; as
          defined in Section 409A of the Code.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If a payment obligation under
          this Agreement arises on account of Executive&#8217;s separation from service while Executive is a &#8220;specified employee&#8221; (as defined under Section 409A of the Code and determined in good faith by the Company), any payment of &#8220;deferred compensation&#8221; (as
          defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12)) that is scheduled to be paid within six (6) months after such separation from service
          shall accrue without interest and shall be paid within fifteen (15) days after the end of the six-month period beginning on the date of such separation from service or, if earlier, within fifteen (15) days after the appointment of the personal
          representative or executor of Executive&#8217;s estate following Executive&#8217;s death.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">18.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Governing Law.</font>&#160; This Agreement shall be governed by, and construed and enforced in accordance with, the laws of New York, without giving effect to the principles of conflicts of law thereof.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">19.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-weight: bold;">Notices.&#160; </font>Any notice provided for in this Agreement shall be provided in writing.&#160; Notices shall be effective from the date of service, if served personally on the Party to whom notice is to be given, or on
          the second day after mailing, if mailed by first class mail, postage prepaid.&#160; Notices shall be properly addressed to the Parties at their respective addresses or to such other address as either Party may later specify by notice to the other.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Dispute Resolution.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive and the Company
          mutually agree that any controversy or claim arising out of or relating to this Agreement or the employment relationship between Executive and the Company, including any dispute regarding the scope or enforceability of this arbitration provision,
          shall be settled by individual arbitration administered by Judicial Arbitration and Mediation Services (JAMS) in accordance with the JAMS Employment Arbitration Rules and Procedures in effect as of the date of this Agreement (&#8220;<u>JAMS Rules</u>&#8221;),
          to the extent the JAMS Rules are consistent with the terms of this provision. Judgment on the award may be entered in any court having jurisdiction thereof.&#160; The parties also mutually agree that, except as otherwise required by enforceable law,
          arbitration shall be the sole and exclusive forum for resolving such disputes (including any dispute with the Company, any related parties, and any of their respective employees, officers, owners or agents, who shall be third-party beneficiaries
          of this provision), and both parties agree that they are hereby waiving any right to have their disputes resolved in civil litigation by a court or jury trial, including but not limited to any disputes arising under statutes such as Title VII of
          the Civil Rights Act, the Age Discrimination in Employment Act, or the California Fair Employment and Housing Act.&#160; The arbitrator&#8217;s decisions on such matters shall be final and binding on the parties to the fullest extent permitted by law.&#160; The
          JAMS Rules are incorporated herein by reference, to the extent they are consistent with the terms of this provision, and may be found at available at https://www.jamsadr.com/rules-employment-arbitration/.&#160; The place of arbitration shall be New
          York County, New York.&#160; Any arbitration hereunder shall be conducted only on an individual basis and not in a class, consolidated, or representative action.&#160; The Company shall pay the administrative costs and fees directly related to the
          arbitration, including the fees of the arbitrator.&#160; Each party shall otherwise bear its own respective attorneys&#8217; fees and costs, including the costs of any depositions or for expert witnesses, unless any applicable law provides otherwise to the
          prevailing party, in which case the arbitrator shall have the authority to award costs and attorneys&#8217; fees to the prevailing party in accordance with the applicable law.&#160; Neither a party nor the arbitrator may disclose the existence, content, or
          results of any arbitration hereunder without the prior written consent of both parties, unless otherwise provided by law.&#160; The parties&#8217; agreement to arbitrate does not apply to claims that, pursuant to applicable law, cannot be subject to
          mandatory arbitration, including claims under the Private Attorney General Act; provided that, in the event of a dispute regarding whether, or the extent to which, any dispute is subject to arbitration, the parties agree that no underlying
          dispute or any facts regarding such dispute shall be submitted to a court until and unless a declaratory judgment is issued by the duly appointed arbitrator that allows a dispute to proceed in court based on a claim by a party that this
          arbitration provision is unenforceable as a matter of law as to an asserted claim.&#160; Moreover, nothing in this Agreement prevents Executive from filing or prosecuting a charge with any government agency (such as the Equal Employment Opportunity
          Commission) over which such agency has jurisdiction, or from participating in an investigation or proceeding conducted by any such agency. Any matter required to be arbitrated under this Section 20 shall be submitted to mediation in a manner
          agreed to by Executive and the Company.&#160; Executive and the Company agree to use mediation to attempt to resolve any such matter prior to filing for arbitration.&#160; Executive and the Company will select a mediator agreeable to both parties.&#160; The
          costs of the mediation and fees of the mediator will be borne entirely by the Company.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY WAIVE THE RIGHT TO BRING AND/OR PARTICIPATE IN ANY CLASS
        OR COLLECTIVE ACTION. THE ARBITRATOR SHALL HAVE NO POWER TO ARBITRATE ANY CLASS AND/OR COLLECTIVE CLAIMS. BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY ARE WAIVING THEIR STATUTORY AND COMMON LAW RIGHTS TO SEEK RELIEF IN A COURT OF
        LAW AND ARE WAIVING THEIR RIGHTS TO A TRIAL BY JURY.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the provisions
          of Section 20(a), the Parties further acknowledge and agree that, due to the nature of the confidential information, trade secrets, and intellectual property belonging to the Company to which Executive has or will be given access, and the
          likelihood of significant harm that the Company would suffer in the event that such information was disclosed to third parties, the Company shall have the right to file suit&#160; in a court of competent jurisdiction to seek injunctive relief to
          prevent Executive from violating the obligations established in Sections 7, 8, 9 or 10 of this Agreement without first submitting the&#160; claim, controversy, or dispute to JAMS mediation or arbitration.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">21.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-weight: bold;">Indemnification.</font>&#160; The Company shall indemnify and hold harmless Executive for any liability to any third-party incurred by reason of any act or omission performed by Executive while acting in good faith on
          behalf of the Company and within the scope of the authority of Executive pursuant to this Agreement and under the rules and policies of the Company, except that Executive must have in good faith believed that such action was in the best interest
          of the Company and such course of action or inaction must not have constituted gross negligence, fraud, willful misconduct, or breach of a fiduciary duty.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">22.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Miscellaneous.</font></font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Compensation Recovery Policy.
          Executive acknowledges and agrees that, to the extent the Company adopts any claw-back or similar policy pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder,
          he or she shall take all action necessary or appropriate to comply with such policy (including, without limitation, entering into any further agreements, amendments or policies necessary or appropriate to implement and/or enforce such policy with
          respect to past, present and future compensation, as appropriate).</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No delay or omission by the
          Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.&#160; A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar
          or waiver of any right on any other occasion.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The captions of the sections of
          this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The language in all parts of
          this Agreement will be construed, in all cases, according to its fair meaning, and not for or against either Party hereto.&#160; The Parties acknowledge that each Party and its counsel have reviewed and revised this Agreement and that the normal rule
          of construction to the effect that any ambiguities are to be resolved against the drafting Party will not be employed in the interpretation of this Agreement.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; The obligations of Company
          under this Agreement, including its obligation to pay the compensation provided for in this Agreement, are contingent upon Executive&#8217;s performance of Executive&#8217;s obligations under this Agreement.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; This Agreement may be executed
          in counterparts, each of which shall constitute an original, but all of which shall constitute one agreement.</font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[Signatures on following page]</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, Executive and the undersigned duly authorized representative of the Company have executed this Agreement as of the date first written below.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z7e9e76018067438aa1b51c3dfc77e2b4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">EXECUTIVE</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="3">
              <div style="text-align: left; color: rgb(0, 0, 0);">/s/Jay Sial</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Jay Sial</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; width: 5%;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt; width: 40%;">July, 6, 2021</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; width: 5%;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: left; color: rgb(0, 0, 0);">/s/Howard J. Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Howard J. Federoff, MD, PhD</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Chief Executive Officer/President</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">July, 6, 2021</div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[<font style="font-style: italic;">Signature Page to Employment Agreement</font>]</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>ADDENDUM A</u></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Job Duties</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z072e59cc58ae408fb3e2dd461e945797" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Update Human Resources (&#8220;HR)&#8221;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z48e92df3d85548f4a5775ec934a1ccda" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Review Professional Employment Organizations: Insperity vs TriNet to recommend approach</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zbfc8d42347274b39b49bece46fab484c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Update employee handbook</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za80305664eec4e3699875bd53ad1e125" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Lead effort to recruit Sr. Director of HR</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zc26645bf392647cfaabcee14b304d632" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Oversee HR functions, searches, building culture that is inclusive, equitable and diverse</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z76d1b0df47d74332ba8f7f122b592bdf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Information Technology (&#8220;IT&#8221;)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze96e764cd06f41198ee155cc988041f2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Cybersecurity review</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zbce80990bf7e4601ba9800da90848e42" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Implement recommendations</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zc4edc6ee34dd4767b2e391ce59664684" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Bring part-time IT expertise that is compatible with publicly traded entity</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z0943608954194194987baa59bae9c3c5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Assume responsibility for web design, function and branding</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z06bf3de6b568404496e748a77cd2c450" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Facilities</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z0f598b5f802a438685cf13f350ba071e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Review the Company&#8217;s Brooklyn, New York site with Quality Assurance support</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zd4539e8ecf1c445381e8ba654286c255" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Review Cambridge, Massachusetts location, assist with buildout and coordinate with Chief Scientific Officer (&#8220;CSO&#8221;) and Factor/Novellus (Matt Angel and Chris Rohde)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb7088ceee32144b6b2890accad2fc1a9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Lead effort with CSO and Chief Medical Officer input to assess cellular manufacturing option</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z74e08c998abc484c8790e0875f35a997" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Manage all aspects of facilities</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z08f5370697044c6aaa1aaaf143f6406e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Investor Relations (&#8220;IR&#8221;)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z139c4c8d48ce41aa8d08254dcfbfdc22" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Intros to CORE IR (Scott Gordon, Pete Serra, Jules Abraham)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8fe4c456b78147a3a6a7457dd6607fc1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Develop understanding of algorithms to chart trader types from New York Stock Exchange</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z50511790c9d1488e83a296028632bff5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Develop a portal that can be managed by CORE IR or internally</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z9b410f158bf549faa1294d7e860c7e0a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Review other IR firms and prepare Request for Proposal</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z7f3a247bed694298ae3d706e1c959f00" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Connect website for &#8220;investors&#8221; to IR firm</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zc4e0ac80d408452d8012e2c9c91af673" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Headquarters Geographic Assessment</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z00950430dc7448a7bad216b394b09949" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Consult with Ernst &amp; Young (Salman Shah) on post-COVID business practices and organizations</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za3c58fa66597432b848024c611f2678e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Scope of work ahead</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z7150f9dcfb7945eab43d5be24f104d55" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 90pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">review cost of business, including but not limited to from a tax perspective, in different venues (e.g., TX, FL, NV, etc.);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8844668d26934ce59ade4b8140963a0b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 90pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">review access to talent in locations;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z573a417ba7be4d51a5e75e26fe065994" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 90pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">review state support/incentives for small cap public companies; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z898ea28f0ccb43fd821a782377e22276" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 90pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">prepare matrix for discussion with President/Chief Executive Officer and Board of Directors</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z34c5e0f29e5c43ac82ed92b16fb5253b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Budget development, forecasting and modeling</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z32445dc4c229483cadd35e742a222f6f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Develop operational unit budget in conjunction with the Vice President of Finance (Sandra Gurrola)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z860267e3135646309c9e7475407c8463" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Allocate resources for remainder of FY21</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1751a5add83e42d0abb8400cb7979492" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Develop Budget for FY22 with unit leaders</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z137817d00d854d1fb15bd261e9a95428" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Strategic Planning</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf314e1ed009a4d68bf23736e144c107b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Develop approach</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za84dfbadf7274a8c81389385a916dda9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Commence planning with stakeholders</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z57dd973cfe02421e87de4a2cc25c6a24" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Publish plan internally for review and periodic updating</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z100ed119b2aa4a508a332ecf1308afc4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Compliance and risk management</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z95e7834cd1f243aa9b403ff4aa4aecd7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Retain compliance and risk management consultant to review gaps and make recommendations</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zecb0711097c14f1089dff9f20f9956f7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Implement recommendations</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z351b5e24346f466da097d01ecfadf4b6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">Hire a director to oversee compliance/risk management</div>
            </td>
          </tr>

      </table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>&#160;ADDENDUM B</u></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CALIFORNIA LABOR CODE SECTION 2870</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; margin-right: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Section 2870 of the California Labor Code provides as follows:</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; text-indent: 36pt; margin-right: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of
        his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except
        for those inventions that either:</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-right: 7.2pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">(1) Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or
        demonstrably anticipated research or development of the employer; or</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; margin-right: 7.2pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">(2) Result from any work performed by the employee for the employer.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; margin-right: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention
        otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>ADDENDUM C</u></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">LIST OF INVENTIONS</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
    </div>
    <div><font style="font-size: 10pt;"> </font>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-family: 'Times New Roman'; font-size: 10pt;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>brhc10027031_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 99.1</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Brooklyn ImmunoTherapeutics Welcomes</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Jay Sial as Chief Administrative Officer</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M3"></a><font style="font-weight: bold;">Brooklyn, NY</font> &#8211; July 13, 2021 &#8211; Brooklyn ImmunoTherapeutics<a name="z_DV_C7"></a>,
        Inc. (NYSE American: BTX) (&#8220;Brooklyn&#8221; or &#8220;the Company&#8221;), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today
        announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021.</div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Jay has a long and impressive history managing the finances of multiple health systems and hospitals and leading the financial
        transformation of complex organizations through prudent management and strategic activities, including fundraising, business development and facilities management. We are truly fortunate to have him join the team at Brooklyn ImmunoTherapeutics,&#8221;
        commented Howard J. Federoff, M.D., Ph.D., Brooklyn&#8217;s Chief Executive Officer and President.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;I am honored to be joining Brooklyn ImmunoTherapeutics which is using cutting edge mRNA based gene editing and cellular reprogramming
        tools and look forward to helping the team bring these therapies to cancer patients,&#8221; said Mr. Sial regarding his new role with Brooklyn.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Prior to joining Brooklyn, Mr. Sial served as Chief Financial Officer at Aspen Neurosciences, a privately-held emerging biotechnology
        company. Before that he served as Chief Financial Officer at multiple complex organizations, including University of California Irvine Health, Trinity Health/Loyola University Health System and University of Kentucky Healthcare. He also served in
        key financial and management roles at Thomas Jefferson University Hospital and FHP, Inc., a health maintenance organization (HMO) based in Fountain Valley, California. He holds a Master&#8217;s of Business Administration (Finance) from Virginia Tech and
        a Bachelor of Arts degree in Economics and Accounting from University of Delhi, India.</div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Brooklyn ImmunoTherapeutics</div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M25"></a>Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer,
        both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreement with Factor
        Bioscience/Novellus Therapeutics.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn&#8217;s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical
        trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M28"></a><a name="z_DV_M29"></a><a name="z_DV_M30"></a><a name="z_DV_M34"></a>###</div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_DV_M35"></a><a name="z_DV_M36"></a><a name="z_DV_M37"></a><a name="z_DV_M38"></a>Investor Relations Contact:</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">CORE IR</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">516-222-2560</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">investors@brooklynitx.com</div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Media Contact:</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">CORE IR</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Jules Abraham</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">julesa@coreir.com</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">917-885-7378</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>btx-20210713.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://brooklynitx.com/20210713" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://brooklynitx.com/20210713" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20210713_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20210713_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>btx-20210713_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>btx-20210713_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20210713.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10027031_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="btx-20210713.xsd" xlink:type="simple"/>
    <context id="c20210713to20210713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20210713to20210713"
      id="Fact_f415bc8cefcd43b5902e25634b5397ec">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="c20210713to20210713"
      id="Fact_6d760d56c6f247b8860f4abc4e25eb3e">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="c20210713to20210713"
      id="Fact_62dbb6e4b9f64f3e9270315c5c36c49c">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="c20210713to20210713"
      id="Fact_821f306f6b784831a9264952dec668e1">140 58TH STREET, BUILDING A</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine1
      contextRef="c20210713to20210713"
      id="Fact_40bb32a5cc484f8b99fa85f11da0311b">140 58TH STREET, BUILDING A</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20210713to20210713"
      id="Fact_417bad00838b4cc18b468c13188f8fac">SUITE 2100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine2
      contextRef="c20210713to20210713"
      id="Fact_536e15c895664d999454310e474dda0a">SUITE 2100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20210713to20210713"
      id="Fact_32af2c526cf34cc997e21080b1f52840">BROOKLYN</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCityOrTown
      contextRef="c20210713to20210713"
      id="Fact_0cb202ce53d34477843f8bae40069abe">BROOKLYN</dei:EntityAddressCityOrTown>
    <dei:EntityCentralIndexKey
      contextRef="c20210713to20210713"
      id="Fact_be66ba8bca5144ea9d2d0f39b78785f1">0000748592</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20210713to20210713"
      id="Fact_568ffa60347948e6bfaad661faa49cf0">NYSEAMER</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20210713to20210713"
      id="Fact_dbba1f22b8514396a794fc52bb2e0c20">NYSEAMER</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20210713to20210713"
      id="Fact_82233f32fbaf4d62a40ed3f5f0d2b183">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20210713to20210713"
      id="Fact_71a5b55383b54489b5a574a4b2fdb015">2021-07-13</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20210713to20210713"
      id="Fact_7829cc03f4114359b8c1953f59bff988">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20210713to20210713"
      id="Fact_63bc1a3b803d4ad8be0997d685dcee94">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20210713to20210713"
      id="Fact_06bfc16f0c3a44c6bac69a90f7231e28">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressStateOrProvince
      contextRef="c20210713to20210713"
      id="Fact_c076ff465d574dc19e689194a0915859">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20210713to20210713"
      id="Fact_5a0071d94ee24c18b2d5bc208563a296">11220</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20210713to20210713"
      id="Fact_02f6e47040ff4b6291442666095f8df3">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20210713to20210713"
      id="Fact_a72610c6d1d347feb7cf0daa95804e92">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20210713to20210713"
      id="Fact_fc429cb3f1d2444da24121ccda4a9600">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20210713to20210713"
      id="Fact_2a8988835846499a8d89f7da68111ef0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20210713to20210713"
      id="Fact_58d9f13c9a854a32bea7ca2708c9e667">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20210713to20210713"
      id="Fact_3c4278b8ccb44e6483ec0dd7d0eb9745">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20210713to20210713"
      id="Fact_da4f168a1f90408193b3a7bb68ea961c">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20210713to20210713"
      id="Fact_084585b3843641e88308e3679a0b90f2">BTX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20210713to20210713"
      id="Fact_789821bfce8345ff9c0e2ee0824a930f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140248713846184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 13,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Brooklyn ImmunoTherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">140 58TH STREET, BUILDING A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 2100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">BROOKLYN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "\B_-2'#AEZC\!   \ @
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M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ O(OS4B0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "\B_-2B4(AANX    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "\
MB_-2F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( +R+\U)%8D*99 0   (1   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "\
MB_-2GZ ;\+$"  #B#   #0              @ &G#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( +R+\U*7BKL<P    !,"   +              "  8,/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +R+\U(<.&7J/P$  #P"   /
M          "  6P0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "\B_-2
M)!Z;HJT   #X 0  &@              @ '8$0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "\B_-299!YDAD!  #/ P  $P
M        @ &]$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   '%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10027031_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10027031_8k.htm">brhc10027031_8k.htm</File>
    <File>brhc10027031_ex10-1.htm</File>
    <File>brhc10027031_ex99-1.htm</File>
    <File>btx-20210713.xsd</File>
    <File>btx-20210713_lab.xml</File>
    <File>btx-20210713_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10027031_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10027031_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btx-20210713_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btx-20210713_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btx-20210713.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 12,
    "total": 12
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "btx",
   "nsuri": "http://brooklynitx.com/20210713",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027031_8k.htm",
      "contextRef": "c20210713to20210713",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://brooklynitx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027031_8k.htm",
      "contextRef": "c20210713to20210713",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-21-024792-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-21-024792-xbrl.zip
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M?DAIX#@Z_ &I%ZY#ON/?S_L'G_MGFP()!#'50\/P7<"3Z3D4( N!PWS?X!I
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ME+]->^:CU.#03*:&AMBDCNL7E6O[AEHYUXJ$=IG@PW[-TI4H&#@'3[KE@(K
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M\""WEWEVU5@,TQNUKW!:2?=H4$TH&&*PQ6ECFI4P)VV1 4J9VER4>8.OVVY
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MO%=X0MS.S3Q357$_T[U+GEV^Y*TWU]S&/46:G;!7&T]+Z9" &DO=W1CD<',
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M14\01,CC3M>P)B^A^OJ,GIY&H>&.P3U+[&+MO$#E9],2]M;5R'^.K10_'"V
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MD>01*#XUUG5Y0,4'MJ:,!H/I;"C$2(S[$[&[.T2:J5WX,0Z_XQ.Q4?4?T[E
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M8'8]N=I=Y=_=PT7S?PK^ U!+ P04    " "\B_-2=)YDXE<#  !Y#P  $
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MK>QSZ36D[<O*$?N8*LBN_@%02P,$%     @ O(OS4O.$* 6!"   <E@  !0
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MA'KP0HQUPTB]!8:O[&6U>G77G8KO<"RMQ14[XM_\6S2%^3?ESOX'4$L#!!0
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M4$L! A0#%     @ O(OS4L7G<4P_9P  8&L" !<              ( !JAH
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G+3(P,C$P-S$S7W!R92YX;6Q02P4&      8 !@"- 0  7IP

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
